Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation with bortezomib and lenalidomide maintenance
2010-018594-37Phase 2Active
- Sponsor
- European Myeloma Network
- Start
- Nov 2012
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bortezomib and lenalidomide in multiple myeloma (MM), sponsored by European Myeloma Network. Primary endpoints: Phase I primary endpoint and Phase II toxicity of maintenance therapy. Started Nov 2012; status: active.
02
Drugs
bortezomiblenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-018594-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018594-37.